Related Experiment Videos
Receptor blockade with monoclonal antibodies as anti-cancer therapy
1Laboratory of Receptor Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Abstract:
Human tumors express high levels of growth factors and their receptors, and many types of malignant cells appear to exhibit autocrine- or paracrine-stimulated growth. Therefore, antireceptor directed therapies have the potential of being useful anti-cancer agents. A series of murine monoclonal antibodies (MAbs) directed against human growth factor receptors and their corresponding growth factors have been produced. MAbs against the receptors for epidermal growth factor, Her2/Neu, transferrin, insulin-like growth factor, interleukin, (IL)-2 and IL-1 are currently being evaluated. MAbs directed against epidermal growth factor, transforming growth factor-alpha, bombesin, IL-2, and IL-6 also are under study. These MAbs have shown promising preclinical activity, and some of them are being tested in clinical trials. So far, anti-tumor responses have been observed with anti-IL-2 receptor, anti-bombesin and anti-IL-6 MAbs. Further research is focusing in the production of "chimeric" and "humanized" MAbs, in order to obviate the problem of host immune reactions.
Insights
Monoclonal antibodies targeting growth factor receptors show promise in cancer therapy. Research is ongoing to develop advanced antibody types for improved anti-tumor responses and reduced immune reactions.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Human tumors often rely on growth factors and their receptors for proliferation.
- Autocrine and paracrine signaling pathways drive malignant cell growth.
- Targeting these growth factor receptors presents a therapeutic strategy for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of murine monoclonal antibodies (MAbs) against human growth factor receptors and growth factors.
- To investigate the potential of these MAbs as anti-cancer agents.
- To explore the development of chimeric and humanized MAbs to minimize host immune responses.
Main Methods:
- Production of murine monoclonal antibodies (MAbs) against various growth factor receptors (e.g., EGFR, Her2/Neu, transferrin, IGF, IL-2, IL-1) and growth factors (e.g., EGF, TGF-α, bombesin, IL-2, IL-6).
- Preclinical evaluation of MAb activity.
- Clinical trials for selected MAbs.
- Research into chimeric and humanized MAb development.
Main Results:
- MAbs targeting receptors for epidermal growth factor, Her2/Neu, transferrin, insulin-like growth factor, IL-2, and IL-1 are under evaluation.
- MAbs against EGF, TGF-α, bombesin, IL-2, and IL-6 are also under study.
- Promising preclinical activity observed for several MAbs.
- Anti-tumor responses documented in clinical trials for anti-IL-2 receptor, anti-bombesin, and anti-IL-6 MAbs.
Conclusions:
- Monoclonal antibodies targeting growth factor receptors and pathways represent a viable therapeutic strategy for cancer.
- Clinical trials have demonstrated anti-tumor activity for specific MAbs.
- Ongoing research focuses on engineering chimeric and humanized MAbs to enhance efficacy and reduce immunogenicity.